Cardio Diagnostics Holdings, Inc. (CDIO) filed an investor presentation detailing its business strategy, market opportunity, and recent operational progress. The update highlights significant reimbursement milestones for its AI-powered cardiovascular diagnostic tests, Epi+Gen CHD and PrecisionCHD, and outlines a multi-channel commercialization plan.

Key Details

  • Reimbursement Progress: The company has secured a final CMS payment rate of $854 per test for both of its products (CPT codes 0439U and 0440U). It has also established initial in-network coverage and out-of-network billing capabilities.
  • Market Opportunity: CDIO estimates a combined total addressable market (TAM) of over $175 billion in the U.S. for its Epi+Gen CHD (~$125B) and PrecisionCHD (~$51B) tests.
  • Operational & Commercial Updates: The company has begun in-house test processing in its CLIA-certified lab, achieving an initial lab cost-of-goods-sold (COGS) reduction of approximately 30%. It is also pursuing international expansion through partnerships in India.